Outlook Therapeutics, Inc.
OTLK· Nasdaq
OTLKOutlook Therapeutics, Inc.
Filed May 15, 2025 · 10-Q · 45 days after period end · 0001558370-25-007873
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$46.36M | -$114.29M | -$6.65M | -$19.70M |
| EPS Diluted | -$1.50 | -$8.01 | -$0.52 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end
